FOXO4-DRI
Also known as: Proxofim, Senolytic Peptide
A senolytic peptide that selectively destroys senescent (zombie) cells by disrupting the FOXO4-p53 interaction that keeps them alive. The first peptide-based senolytic.
Mechanism of Action
Competes with endogenous FOXO4 for p53 binding. In senescent cells that depend on FOXO4-p53 interaction for survival, this releases p53 to the mitochondria to trigger apoptosis. Normal cells are unaffected.
Dosing Protocol
Research protocols: 5 mg/kg IV every 3 days for 3 doses in mouse studies. Human dosing not established.
Open peptide calculatorReconstitution
Research-grade: lyophilized, reconstitute in sterile water.
Storage
Lyophilized: -80°C preferred, -20°C acceptable. Very expensive compound.
Side Effects
- ●Limited human data
- ●Theoretical risk of affecting non-senescent cells at high doses
Key Research Findings
- ●Restored fitness, fur density, and renal function in aged mice (Cell 2017)
- ●Selectively killed senescent cells while sparing healthy cells
- ●First demonstration of peptide-based senolytic approach
Latest Verified Lab Report
No lab reports available for FOXO4-DRI yet.
Community-funded testing results will appear here.
Vendor Trust Leaderboard
Trust leaderboard coming soon.
Vendor rankings based on verified lab test results.
Active Deals
15% off with code at checkout.
10% off with code at checkout.
10% off — discount applied automatically via referral link.
10% off with code at checkout.
Sponsored Ad Space
Advertise with usResearch Use Only
This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.